In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per ...

The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

With Axtria Ignite 2025 just around the corner, attention turns to how the life sciences industry is preparing for the next ...

Zaynich is based on cefepime, a well-established beta-lactam antibiotic, combined with a novel beta-lactamase inhibitor ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...

The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory ...

Meanwhile, BioNTech itself bought into the category with its takeover of BNT327's developer Biotheus unit last year for what ...

Added to that, 23andMe suffered a massive data breach in 2023 that resulted in information from about 7 million people being ...

In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head ...